Hormone replacement therapy increases the risk of cranial meningioma

  • Lene Andersen
    Affiliations
    Department of Neurology, Odense University Hospital, Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Sdr. Boulevard 29, 5000 Odense C, Denmark
    Search for articles by this author
  • Søren Friis
    Affiliations
    Danish Cancer Society Research Centre, Strandboulevarden 49, 2100 Copenhagen Ø, Denmark

    Department of Public Health, University of Copenhagen, Strandboulevarden 49, 2100 Copenhagen Ø, Denmark
    Search for articles by this author
  • Jesper Hallas
    Affiliations
    Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, J.B. Winsløws Vej 19, 2.sal, 5000 Odense C, Denmark
    Search for articles by this author
  • Pernille Ravn
    Affiliations
    Department of Gynecology, Odense University Hospital, Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Sdr. Boulevard 29, 5000 Odense C, Denmark
    Search for articles by this author
  • Henrik Daa Schrøder
    Affiliations
    Department of Pathology, Institute of Clinical Research, Odense University Hospital, Winsløwparken 15, 5000 Odense C, Denmark
    Search for articles by this author
  • David Gaist
    Correspondence
    Corresponding author: Address: Department of Neurology, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark. Tel.: +45 6541 2485; fax: +45 6541 3389.
    Affiliations
    Department of Neurology, Odense University Hospital, Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Sdr. Boulevard 29, 5000 Odense C, Denmark
    Search for articles by this author

      Abstract

      Aim

      We investigated the influence of hormone replacement therapy (HRT) use on the risk of meningioma in a population-based setting.

      Methods

      We conducted a nationwide case–control study in Denmark based on population-based administrative and health registries. The study included all female patients aged 55–84 years with a first time diagnosis of meningioma during 2000–2009. The cases were matched on birth year with female population controls. Ever use of HRT since 1995 was defined as ⩾2 HRT prescriptions and categorised according to HRT type (oestrogen only, combined oestrogen–progestagen, and progestagen only) and cumulated duration of use (<1, ⩾1 to <5, ⩾5 to <10, ⩾10 years). We used conditional logistic regression to compute odds ratios (ORs), with 95% confidence intervals (CIs), for meningioma associated with HRT use, and adjusting for potential confounders.

      Results

      We identified 924 cases and 6122 controls. Ever use of HRT was associated with an increased risk of meningioma (OR, 1.3; 95% CI, 1.1–1.5) compared with non-use (0–1 prescriptions). The risk increased with increasing duration of HRT use, reaching an OR of 1.7 (95% CI, 1.2–2.3) after more than 10 years of use. The risk of meningioma associated with long-term (⩾10 years) HRT use was most pronounced for combined oestrogen–progestagen therapy (OR, 2.2; 95% CI, 1.4–3.3), especially when this regimen constituted the sole HRT therapy (OR, 2.7; 95% CI, 0.9–7.5), although the latter estimate was based on small numbers.

      Conclusions

      Long-term HRT use, particularly of combined oestrogen–progestagen therapy, may increase the risk of meningioma.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Bondy M.L.
        • Scheurer M.E.
        • Malmer B.
        • et al.
        Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.
        Cancer. 2008; 113: 1953-1968
        • Wiemels J.
        • Wrensch M.
        • Claus E.B.
        Epidemiology and etiology of meningioma.
        J Neurooncol. 2010; 99: 307-314
        • Klaeboe L.
        • Lonn S.
        • Scheie D.
        • et al.
        Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968–1997.
        Int J Cancer. 2005; 117: 996-1001
        • Deltour I.
        • Johansen C.
        • Auvinen A.
        • et al.
        Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974–2003.
        J Natl Cancer Inst. 2009; 101: 1721-1724
        • Jhawar B.S.
        • Fuchs C.S.
        • Colditz G.A.
        • et al.
        Sex steroid hormone exposures and risk for meningioma.
        J Neurosurg. 2003; 99: 848-853
        • Hatch E.E.
        • Linet M.S.
        • Zhang J.
        • et al.
        Reproductive and hormonal factors and risk of brain tumors in adult females.
        Int J Cancer. 2005; 114: 797-805
        • Custer B.
        • Longstreth Jr., W.T.
        • Phillips L.E.
        • et al.
        Hormonal exposures and the risk of intracranial meningioma in women: a population-based case–control study.
        BMC Cancer. 2006; 6: 152
        • Lee E.
        • Grutsch J.
        • Persky V.
        • et al.
        Association of meningioma with reproductive factors.
        Int J Cancer. 2006; 119: 1152-1157
        • Wigertz A.
        • Lonn S.
        • Mathiesen T.
        • et al.
        Risk of brain tumors associated with exposure to exogenous female sex hormones.
        Am J Epidemiol. 2006; 164: 629-636
        • Blitshteyn S.
        • Crook J.E.
        • Jaeckle K.A.
        Is there an association between meningioma and hormone replacement therapy?.
        J Clin Oncol. 2008; 26: 279-282
        • Korhonen K.
        • Raitanen J.
        • Isola J.
        • et al.
        Exogenous sex hormone use and risk of meningioma: a population-based case–control study in Finland.
        Cancer Causes Control. 2010; 21: 2149-2156
        • Michaud D.S.
        • Gallo V.
        • Schlehofer B.
        • et al.
        Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study.
        Cancer Epidemiol Biomarkers Prev. 2010; 19: 2562-2569
        • Benson V.S.
        • Pirie K.
        • Green J.
        • et al.
        Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study.
        Int J Cancer. 2010; 127: 1692-1698
        • Korhonen K.
        • Auvinen A.
        • Lyytinen H.
        • et al.
        A nationwide cohort study on the incidence of meningioma in women using postmenopausal hormone therapy in Finland.
        Am J Epidemiol. 2012; 175: 309-314
        • Cea-Soriano L.
        • Blenk T.
        • Wallander M.A.
        • et al.
        Hormonal therapies and meningioma: is there a link?.
        Cancer Epidemiol. 2012; 36: 198-205
        • Tucha O.
        • Smely C.
        • Preier M.
        • et al.
        Preoperative and postoperative cognitive functioning in patients with frontal meningiomas.
        J Neurosurg. 2003; 98: 21-31
        • Thygesen L.C.
        • Ersboll A.K.
        Danish population-based registers for public health and health-related welfare research: introduction to the supplement.
        Scand J Public Health. 2011; 39: 8-10
        • Pedersen C.B.
        The Danish civil registration system.
        Scand J Public Health. 2011; 39: 22-25
        • Storm H.H.
        • Michelsen E.V.
        • Clemmensen I.H.
        • et al.
        The Danish Cancer Registry – history, content, quality and use.
        Dan Med Bull. 1997; 44: 535-539
        • Gjerstorff M.L.
        The Danish Cancer Registry.
        Scand J Public Health. 2011; 39: 42-45
        • Kildemoes H.W.
        • Sorensen H.T.
        • Hallas J.
        The Danish National Prescription Registry.
        Scand J Public Health. 2011; 39: 38-41
        • Lynge E.
        • Sandegaard J.L.
        • Rebolj M.
        The Danish National Patient Register.
        Scand J Public Health. 2011; 39: 30-33
        • Jensen V.M.
        • Rasmussen A.W.
        Danish education registers.
        Scand J Public Health. 2011; 39: 91-94
        • Rothman K.J.
        • Greenland S.
        • Lash T.L.
        Modern epidemiology.
        3rd ed. Wolters Kluwer Health, Lippencott Williams & Wilkins, Philadelphia2008
        • WHO
        Guidelines for ATC classification and DDD assignment 2011.
        WHO Collaborating Center for Drug Statistics Methodology, Oslo2010
        • Schoemaker M.J.
        • Swerdlow A.J.
        • Hepworth S.J.
        • et al.
        History of allergic disease and risk of meningioma.
        Am J Epidemiol. 2007; 165: 477-485
        • Wiemels J.L.
        • Wrensch M.
        • Sison J.D.
        • et al.
        Reduced allergy and immunoglobulin E among adults with intracranial meningioma compared to controls.
        Int J Cancer. 2011; 129: 1932-1939
        • Carstensen B.
        • Witte D.R.
        • Friis S.
        Cancer occurrence in Danish diabetic patients: duration and insulin effects.
        Diabetologia. 2012; 55: 948-958
        • Schneider B.
        • Pulhorn H.
        • Rohrig B.
        • et al.
        Predisposing conditions and risk factors for development of symptomatic meningioma in adults.
        Cancer Detect Prev. 2005; 29: 440-447
        • Fisher J.L.
        • Schwartzbaum J.A.
        • Wrensch M.
        • et al.
        Epidemiology of brain tumors.
        Neurol Clin. 2007; 25 (867–90, vii)
        • Blenstrup L.T.
        • Knudsen L.B.
        Danish registers on aspects of reproduction.
        Scand J Public Health. 2011; 39: 79-82
        • Custer B.S.
        • Koepsell T.D.
        • Mueller B.A.
        The association between breast carcinoma and meningioma in women.
        Cancer. 2002; 94: 1626-1635
        • IARC
        A review of human carcinogens. Part A: pharmaceuticals.
        International Agency for Research on Cancer, Lyon2008
        • Benson V.S.
        • Pirie K.
        • Green J.
        • et al.
        Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort.
        Br J Cancer. 2008; 99: 185-190